---
title: "Weekly Recap | Twist Bioscience +3.19%, consensus target below spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300855375.md"
description: "Twist Bioscience rose 3.19% this week to $188.67, outperforming the S&P 500 by about 3.46 percentage points. The week saw a wide 13.91% range: Monday dipped to $175.02 before recovering, Wednesday climbed towards $197.19, and Thursday touched a 60-day high of $200.31 intraday before easing back to end the week at $188.67. The overall shape was a choppy advance that faded from its peak."
datetime: "2026-10-03T08:40:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300855375.md)
  - [en](https://longbridge.com/en/news/300855375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300855375.md)
generator: "portal-rs"
---

# Weekly Recap | Twist Bioscience +3.19%, consensus target below spot

## The Week

Twist Bioscience rose 3.19% this week to $188.67, outperforming the S&P 500 by about 3.46 percentage points. The week saw a wide 13.91% range: Monday dipped to $175.02 before recovering, Wednesday climbed towards $197.19, and Thursday touched a 60-day high of $200.31 intraday before easing back to end the week at $188.67. The overall shape was a choppy advance that faded from its peak.

## Key Events

The company itself had no major product, earnings, or regulatory news this week. Instead, the focus sat on price action near record highs. After-hours trading on Monday rose 5.55%, with a pullback following nine consecutive days of new highs. Tuesday marked a fresh one-year high. Wednesday’s pre-market session gained another 3.15% after a target price was raised to $190, pushing the share to a 52-week high. Thursday placed TWST among biotech names hitting 52-week highs. The week’s flow was dominated by momentum headlines rather than company-specific catalysts.

## Analyst Ratings

Among the 13 brokers covering Twist Bioscience, 7 rate it buy, 2 overweight, 3 hold, and 1 sell. The consensus rating is buy, with a consensus target price of $120.83, about 36% below spot. The target range is wide, from a low of $36 to a high of $212, signalling sharp disagreement. The stock ranks 81st out of 507 names in the biotech industry by rating.

## The Week Ahead

Twist Bioscience has no scheduled earnings or event calendar next week, but macro data is heavy. Monday brings the final U.S. services PMI and ISM non-manufacturing PMI, Tuesday has trade balance figures, and Wednesday includes EIA crude inventory data. Biotech is sensitive to shifts in rates and risk appetite, so these prints could shape sector-wide fund flows.

## In Short

Twist Bioscience pushed towards record highs and beat the broader market this week, yet the broker consensus target sits about 36% below spot and the target range is extremely wide, pointing to real disagreement about the long-term path. The latest session faded from its high, leaving macro data and money flows as the key signals for this high-flying sector.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [TWST.US](https://longbridge.com/en/quote/TWST.US.md)

## Related News & Research

- [Twist Bioscience CEO Emily M. Leproust disposes of 5,203 common shares worth $921,493.96](https://longbridge.com/en/news/300161715.md)
- [BUZZ-Leerink sees life-science tools benefiting from Anthropic's push into biology](https://longbridge.com/en/news/300019173.md)
- [Trade Gap Expected to Widen — Data Week Ahead](https://longbridge.com/en/news/300818310.md)
- [Blue Owl maintains 5% tender cap on two BDCs amid elevated withdrawal requests](https://longbridge.com/en/news/300818386.md)
- [Constellation Brands Stock Forecast: Beer Demand Faces a Key Q2 Earnings Test](https://longbridge.com/en/news/300859275.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**